Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2018

Open Access 01-06-2018 | Epidemiology

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies

Authors: E. Rakovitch, R. Gray, F. L. Baehner, R. Sutradhar, M. Crager, S. Gu, S. Nofech-Mozes, S. S. Badve, W. Hanna, L. L. Hughes, W. C. Wood, N. E. Davidson, L. Paszat, S. Shak, J. A. Sparano, L. J. Solin

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Login to get access

Abstract

Purpose

Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The DCIS score (DS) was validated as a predictor of LR in E5194 and Ontario DCIS cohort (ODC) after BCS. We combined data from E5194 and ODC adjusting for clinicopathological factors to provide refined estimates of the 10-year risk of LR after treatment by BCS alone.

Methods

Data from E5194 and ODC were combined. Patients with positive margins or multifocality were excluded. Identical Cox regression models were fit for each study. Patient-specific meta-analysis was used to calculate precision-weighted estimates of 10-year LR risk by DS, age, tumor size and year of diagnosis.

Results

The combined cohort includes 773 patients. The DS and age at diagnosis, tumor size and year of diagnosis provided independent prognostic information on the 10-year LR risk (p ≤ 0.009). Hazard ratios from E5194 and ODC cohorts were similar for the DS (2.48, 1.95 per 50 units), tumor size ≤ 1 versus  > 1–2.5 cm (1.45, 1.47), age ≥ 50 versus < 50 year (0.61, 0.84) and year ≥ 2000 (0.67, 0.49). Utilization of DS combined with tumor size and age at diagnosis predicted more women with very low (≤ 8%) or higher (> 15%) 10-year LR risk after BCS alone compared to utilization of DS alone or clinicopathological factors alone.

Conclusions

The combined analysis provides refined estimates of 10-year LR risk after BCS for DCIS. Adding information on tumor size and age at diagnosis to the DS adjusting for year of diagnosis provides improved LR risk estimates to guide treatment decision making.
Appendix
Available only for authorised users
Literature
2.
go back to reference (EBCTCG) EBCTCG, Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, et al. (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr, 162–177 (EBCTCG) EBCTCG, Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, et al. (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr, 162–177
3.
go back to reference Rakovitch E, Nofech-Mozes S, Narod S, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Sengupta S, Elavathil L et al (2013) Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat 138(2):581–590CrossRefPubMed Rakovitch E, Nofech-Mozes S, Narod S, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Sengupta S, Elavathil L et al (2013) Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat 138(2):581–590CrossRefPubMed
4.
go back to reference Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMed Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMed
5.
go back to reference Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A et al (2015) Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33(33):3938–3944CrossRefPubMedPubMedCentral Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A et al (2015) Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33(33):3938–3944CrossRefPubMedPubMedCentral
6.
go back to reference Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the eastern cooperative oncology group. J Clin Oncol 27(32):5319–5324CrossRefPubMedPubMedCentral Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the eastern cooperative oncology group. J Clin Oncol 27(32):5319–5324CrossRefPubMedPubMedCentral
7.
go back to reference Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW et al (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710CrossRefPubMedPubMedCentral Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW et al (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710CrossRefPubMedPubMedCentral
8.
go back to reference Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA et al (2015) A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152(2):389–398CrossRefPubMedPubMedCentral Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA et al (2015) A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152(2):389–398CrossRefPubMedPubMedCentral
9.
go back to reference Crager MR, Tang G (2014) Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. J Appl Stat 41(12):2676–2695CrossRefPubMedPubMedCentral Crager MR, Tang G (2014) Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. J Appl Stat 41(12):2676–2695CrossRefPubMedPubMedCentral
10.
go back to reference Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Sengupta S, Elavathil L et al (2013) Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat 138(2):581–590CrossRefPubMed Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Sengupta S, Elavathil L et al (2013) Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat 138(2):581–590CrossRefPubMed
11.
go back to reference Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Baehner FL, Miller DP, Fong C, Gu S, Tuck A, Sengupta S, et al. (2017) Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst, 109(4) Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Baehner FL, Miller DP, Fong C, Gu S, Tuck A, Sengupta S, et al. (2017) Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst, 109(4)
12.
go back to reference Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL et al (2009) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133(10):1515–1538PubMed Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL et al (2009) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133(10):1515–1538PubMed
13.
go back to reference Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y (2008) Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol 167(3):362–368CrossRefPubMed Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y (2008) Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol 167(3):362–368CrossRefPubMed
14.
go back to reference Subhedar P, Olcese C, Patil S, Morrow M, Van Zee K (2015) Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 22(10):3273–3281CrossRefPubMedPubMedCentral Subhedar P, Olcese C, Patil S, Morrow M, Van Zee K (2015) Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 22(10):3273–3281CrossRefPubMedPubMedCentral
Metadata
Title
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
Authors
E. Rakovitch
R. Gray
F. L. Baehner
R. Sutradhar
M. Crager
S. Gu
S. Nofech-Mozes
S. S. Badve
W. Hanna
L. L. Hughes
W. C. Wood
N. E. Davidson
L. Paszat
S. Shak
J. A. Sparano
L. J. Solin
Publication date
01-06-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4693-2

Other articles of this Issue 2/2018

Breast Cancer Research and Treatment 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine